Adipokine Imbalance in the Pericardial Cavity of Cardiac and Vascular Disease Patients

Elie, Atlanta G.I.M.; Jensen, Pia Søndergaard; Nissen, Katrine Dueholm; Geraets, Ilvy M. E.; Xu, Aimin; Song, Erfei; Hansen, Maria Lyck; Irmukhamedov, Akhmadjon; Rasmussen, Lars Melholt; Wang, Yu; De Mey, Jo G. R.

Published in:
P L o S One

DOI:
10.1371/journal.pone.0154693

Publication date:
2016

Document version
Final published version

Document license
CC BY

Citation for published version (APA):
Elie, A. G. I. M., Jensen, P. S., Nissen, K. D., Geraets, I. M. E., Xu, A., Song, E., ..., De Mey, J. G. R. (2016). Adipokine Imbalance in the Pericardial Cavity of Cardiac and Vascular Disease Patients. P L o S One, 11(5), [e0154693]. https://doi.org/10.1371/journal.pone.0154693

Terms of use
This work is brought to you by the University of Southern Denmark through the SDU Research Portal. Unless otherwise specified it has been shared according to the terms for self-archiving. If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying this open access version.

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim. Please direct all enquiries to puresupport@bib.sdu.dk

Download date: 05. Mar. 2020
Adipokine Imbalance in the Pericardial Cavity of Cardiac and Vascular Disease Patients

Atlanta G. I. M. Elie1, Pia S. Jensen2, Katrine D. Nissen1, Ivy M. E. Geraets1,3, Aimin Xu4, Erfel Song4, Maria L. Hansen5,6, Akhmadjon Irmukhamedov5,6, Lars M. Rasmussen2,6, Yu Wang4, Jo G. R. De Mey1,3,5,6

1 Dept. Cardiovascular and Renal Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark, 2 Dept. Clinical Biochemistry and Pharmacology, Odense University Hospital, Odense, Denmark, 3 Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands, 4 State Key Laboratory of Pharmaceutical Biotechnology and Dept. Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China, 5 Dept. Cardio-Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark, 6 Centre for Individualized Medicine in Arterial Diseases (CIMA), Odense University Hospital, Odense, Denmark

* jdemey@health.sdu.dk

Abstract

Aim
Obesity and especially hypertrophy of epicardial adipose tissue accelerate coronary atherogenesis. We aimed at comparing levels of inflammatory and atherogenic hormones from adipose tissue in the pericardial fluid and circulation of cardiovascular disease patients.

Methods and Results
Venous plasma (P) and pericardial fluid (PF) were obtained from elective cardiothoracic surgery patients (n = 37). Concentrations of leptin, adipocyte fatty acid-binding protein (A-FABP) and adiponectin (APN) were determined by enzyme-linked immunosorbent assays (ELISA). The median concentration of leptin in PF (4.3 (interquartile range: 2.8–9.1) μg/L) was comparable to that in P (5.9 (2.2–11) μg/L) and these were significantly correlated to most of the same patient characteristics. The concentration of A-FABP was markedly higher (73 (28–124) versus 8.4 (5.2–14) μg/L) and that of APN was markedly lower (2.8 (1.7–4.2) versus 13 (7.2–19) mg/L) in PF compared to P. APN in PF was unlike in P not significantly related to age, body mass index, plasma triglycerides or coronary artery disease. PF levels of APN, but not A-FABP, were related to the size of paracardial adipocytes. PF levels of APN and A-FABP were not related to the immunoreactivity of paracardial adipocytes for these proteins.

Conclusion
In cardiac and vascular disease patients, PF is enriched in A-FABP and poor in APN. This adipokine microenvironment is more likely determined by the heart than by the circulation or paracardial adipose tissue.
Introduction

Obesity promotes atherosclerosis [1, 2]. Hypertrophic chronically inflamed adipose tissues produce less signaling molecules with vascular protective actions such as adiponectin (APN) [3, 4] and more hormones with inflammatory and atherogenic effects such as leptin [5] and adipocyte fatty acid-binding protein (A-FABP) [6]. The circulating hormonal levels of these adipokines are likely dominated by the large subcutaneous and abdominal visceral adipose tissue depots [7].

Local accumulation of fat on the outer surface of the heart around the coronary arteries (epicardial adipose tissue (EAT) [8, 9]) is associated with coronary artery disease (CAD) in not only obese but also non-obese patients [10–15]. This indicates local paracrine effects of adipokines on coronary arteries [8, 16, 17]. Paired comparisons of EAT with subcutaneous or abdominal visceral adipose tissue biopsies revealed differences in fatty acid composition [18], expression and release of chemokines and inflammatory cytokines along with retention of inflammatory cells [15, 19] and in expression and secretion of adipokines [14, 15, 17, 20].

The composition of the pericardial fluid (PF) surrounding the heart has been proposed to be comparable to that of the interstitium of the heart [21, 22]. Several angiogenic growth factors, cytokines, natriuretic peptides and classical vasoactive hormones are present at higher concentration in the PF than in the circulating plasma (P) of patients with ischemic heart disease or heart failure [21, 23–25].

Here we tested the hypothesis that the pericardial cavity of cardiovascular disease (CVD) patients is a unique adipokine microenvironment. To this end we compared the levels of leptin, A-FABP and APN in the PF and P of cardiothoracic surgery patients.

Material and Methods

Subjects and sample collection

The study was performed in accordance with institutional guidelines and was approved by the Medical Ethical Committee of the Region of Southern Denmark (S-20100044). Investigations were performed conform the principles outlined in the Declaration of Helsinki and informed written consent was obtained from all patients. Between September 2013 and January 2014 consecutive patients who underwent elective coronary artery bypass grafting (CABG) or cardiac valve replacement surgeries were enrolled. Clinical information was obtained from the patients’ medical records. On the day before surgery, peripheral venous blood was drawn into pyrogen-free tubes with K$_2$EDTA as an anticoagulant. Pericardial fluid (2–5 mL in K$_2$EDTA and aprotinin) and a biopsy from the parietal sheet of the pericardium (2 x 2 cm) were obtained after median sternotomy and section of the pericardium at outset of the heart surgeries. The blood and pericardial fluid samples were centrifuged (3220 g for 10 min at 4°C) and the supernatants were stored at -80°C until analysis. The pericardial tissue biopsies were fixed in neutral buffered formalin for 48 hours at room temperature. Patients with haemolytic pericardial fluid samples were not further considered. Analyses were limited to the plasma, pericardial fluid and pericardial tissue biopsy from the same individual patients (N = 37). Routine plasma analyses for HbA1c, lipids, creatinine and high sensitivity C-reactive protein (hsCRP) were performed at the Odense University Hospital clinical biochemistry laboratory. Characteristics of the patients were disclosed to the researchers of the pericardial samples after they finalized their data collection. These characteristics are summarized in Table 1.
Measurements of adipokine concentrations

The levels of APN and A-FABP in P and PF were measured by the respective sandwich ELISA kits (Antibody and Immunoassay Services (AIS), The University of Hong Kong, Hong Kong, China) as previously described [26, 27]. P and PF levels of leptin were determined with an ELISA kit from Biovendor Laboratories (Brno, Czech Republic) as previously described [27]. All samples were determined in duplicate. For one patient, plasma A-FABP was below the detection limit.

Table 1. Patient properties, plasma characteristics and prescribed medications.

| Property                      | N  | CABG / valve / both (%)# | Age (years) | Male (%) | Smoking Y / F / N (%) | BMI (kg/m²) | Systolic BP (mmHg) | Diastolic BP (mmHg) | Ejection fraction (%) | Known hypertension (%) | Type 2 diabetes (%) | Dyslipidemia (%) |
|-------------------------------|----|--------------------------|-------------|----------|-----------------------|-------------|--------------------|----------------------|------------------------|-----------------------|---------------------|------------------|
| N                             | 37 | 54 / 27 / 19             | 68 ± 9      | 84       | 14 / 49 / 38          | 28.8 ± 4.9  | 137 ± 21          | 74 ± 13              | 55 (30–70)            | 70                    | 49                  | 81               |
| Plasma concentrations         |    |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| hSCRP (mg/L)                  | 3.9| (1.8–8.4)                |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| HbA1c (mmol/mol)              | 40 | (35–48)                  |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Total cholesterol (mmol/L)    | 3.6| (3.2–4.3)                |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| LDL cholesterol (mmol/L)      | 1.9| (1.6–2.5)                |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| HDL cholesterol (mmol/L)      | 1.1| (0.9–1.3)                |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Triglycerides (mmol/L)        | 1.43| ± 0.63                   |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Creatinine (μmol/L)           | 90 | (78–111)                 |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Medications                   |    |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Aspirin (%)                   | 65 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Other anti-coagulant (%)      | 32 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Statin (%)                    | 76 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| ACEI/ARB (%)                  | 41 | 16                       |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Beta blocker (%)              | 60 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Calcium antagonist (%)        | 32 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Thiazide diuretic (%)         | 21 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Loop diuretic (%)             | 27 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Aldosterone antagonist (%)    | 14 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Insulin (%)                   | 14 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Biguanide (%)                 | 35 |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |
| Sulfoniyurea (%)              | 8  |                          |             |          |                       |             |                    |                      |                        |                       |                    |                  |

Categorical data are shown as % of the study group, normally distributed continuous variables as mean ± SD, non-normally distributed continuous variables as median value (interquartile range).

#, type of surgery. CABG, coronary artery bypass surgery; BMI, body mass index; BP, blood pressure; hSCRP, high sensitivity C-reactive protein; ACEI/ARB, inhibitor of angiotensin converting enzyme or antagonist of angiotensin AT1 receptors.

doi:10.1371/journal.pone.0154693.t001

Measurements of adipokine concentrations

The levels of APN and A-FABP in P and PF were measured by the respective sandwich ELISA kits (Antibody and Immunoassay Services (AIS), The University of Hong Kong, Hong Kong, China) as previously described [26, 27]. P and PF levels of leptin were determined with an ELISA kit from Biovendor Laboratories (Brno, Czech Republic) as previously described [27]. All samples were determined in duplicate. For one patient, plasma A-FABP was below the detection limit.
Western blotting

For detection of different oligomeric complexes of APN, P and PF samples were incubated with nonreducing sample buffer (1% SDS, 5% glycerol, and 10 mM Tris-HCl (pH 6.8)) at room temperature for 10 min, separated by 4–20% gradient SDS-PAGE, transferred to polyvinylidene difluoride membranes, and immunoblotted with affinity-purified rabbit anti-human APN IgG (AIS; 0.2 μg/mL) as we described previously [28]. Based on the ELISA results, samples containing the same amount of total APN (20 ng) were analyzed by non-reducing SDS-PAGE and Western blotting for detection of the distribution of oligomers of APN. Quantification was performed by densitometric analysis using ImageJ software (National Institutes of Health, Bethesda, MA, USA). Increasing concentrations of recombinant human Flag-tagged APN protein purified from mammalian cells were used to generate the standard curves and to establish the specificity of the experimental approach in comparison to P and PF samples from 3 randomly selected patients (S1 Fig). Abundance of APN oligomers with molecular weight > 200 kDa was expressed as % of total APN.

Immunohistochemistry

Presence and distribution of A-FABP and APN in pericardial tissue biopsies were determined by immunohistochemical (IHC) staining. Paraffin sections (5 μm) of formalin-fixed tissue were rehydrated and endogenous peroxidase activity was quenched with H2O2 in methanol. Microwave treatment was used for heat induced antigen retrieval using citrate (for APN) or Tris-ethylene glycol (TEG, for A-FABP). Sections were incubated overnight at 4°C with primary monoclonal antibody against APN (1:500, ab22554, ABCAM, Cambridge, UK) or polyclonal antibody against A-FABP (1:1200, 11030, AIS, Hong Kong, China) followed by incubation with goat anti-mouse or goat anti-rabbit secondary antibody, respectively (both 1:1000, P0447 and P0448 resp. Dako, Denmark) for 45 minutes. Colorimetric detection was completed with 3,3′-diaminobenzidine (DAB). Sections were counterstained with Mayer’s hematoxylin. Sections without primary antibody served as negative controls. Digital images were obtained with a microscope (Olympus BX51, Japan) and imaging software (cellSens Entry, Olympus Corporation, version 1.7). To estimate the size and adipokine content of adipocytes, histological sections were viewed at 10x magnification and analyzed with ImageJ software (version 2.0.0-rc-23; NIH, Bethesda, MD, USA). Adipocyte cross-sectional area was determined as described by Chen and Farese [29]. The percentage of adipocytes staining for APN or A-FABP was evaluated in 3–50 square fields (60000 pixels) depending on the thickness of the paracardial adipose tissue.

Statistics

Continuous variables that were normally distributed are shown as mean ± standard deviation (SD). Concentrations of biomarkers that were not normally distributed (Shapiro-Wilk normality test) are shown as median value and interquartile range (IQR). Paired comparisons between observations in P and PF samples of the same individuals were performed with Wilcoxon matched-pairs signed rank tests. Associations between the levels of adipokines in PF and P and between adipokine concentrations and clinical variables were evaluated with Pearson’s correlation tests after Log10 transformation of the data which resulted in normal distribution. Statistical analyses were performed with GraphPad Prism v6.05 (GraphPad Software Inc, San Diego, Ca, USA) and IBM SPSS (statistical package for the social sciences softwares; Chicago, Il, USA). Differences and associations were considered statistically significant at \( p < 0.05 \).
Results

Patient characteristics

Table 1 summarizes demographic, clinical and plasma characteristics of the study group. Patients were undergoing CABG (54%), cardiac valve replacement (27%) or both (19%) indicating that 73% were suffering from ischemic heart disease due to CAD. As expected, the majority were elderly overweight males (84%) with a high prevalence of systemic inflammation (high plasma hsCRP levels), dyslipidemia (81%), hypertension (70%) and type 2 diabetes (49%) but not overt heart failure or renal failure as judged from ejection fraction and plasma creatinine. Most had been prescribed a variable combination of anti-coagulant, cholesterol lowering, renin angiotensin system inhibitory, anti-hypertensive and anti-diabetic medications.

Pericardial fluid levels of leptin, A-FABP and APN

The concentrations of leptin in PF were comparable to those in the circulating P (4.3 (2.8–9.1) versus 5.9 (2.2–11) μg/L, p = 0.4344; Fig 1A). A-FABP, on the other hand, was 9 times more abundant in PF than P (73 (28–124) versus 8.4 (5.2–14) μg/L, p < 0.0001; Fig 1B) while total APN was 5 times less concentrated in PF than P (2.8 (1.7–4.2) versus 13 (7.2–19) mg/L, p < 0.0001; Fig 1C; Table 2). As a consequence, the leptin/APN ratio was significantly larger in PF than P (2.2 (1.2–3.1) versus 0.44 (0.15–0.82) μg/mg; 5 fold). For A-FABP the imbalance was even more marked. The A-FABP/APN ratio was on average more than 30 times larger in PF

![Fig 1. Venous plasma and pericardial fluid concentrations of leptin (left), adipocyte fatty acid-binding protein (A-FABP, middle) and adiponectin (right) in cardiac and vascular disease patients (n = 36–37). Top, box plots illustrating median values, interquartile range and range of concentrations compared by Wilcoxon matched-pairs signed rank test. Bottom, double logarithmic plots by Pearson’s correlation illustrating the relationship between pericardial fluid concentrations and circulating levels of the adipokines.](https://doi.org/10.1371/journal.pone.0154693.g001)
than in venous P (24 (9.4–70) versus 0.69 (0.35–1.5) μg/mg). Despite marked differences between the levels of especially A-FABP and APN in PF and P, the concentrations of each of leptin, A-FABP and APN in PF were positively correlated to those in the venous plasma (Fig 1D–1F).

Western blotting was used to determine the relative abundance of multimers of APN. Typical results for PF and P from the same individual patients are shown in Fig 2. The contribution of high molecular weight APN (molecular weight > 200 kDa) to total APN did not differ significantly between PF and venous P (29.1 ± 7.5 and 27.4 ± 6.8%, respectively).

### Paracardial adipose tissue properties

Fig 3 illustrates structural features and distribution of A-FABP and APN in the parietal sheet of the pericardium. Mesothelial cells that line the pericardial cavity lay on a thick collagen band. Abluminally from this structure, a vascular network [30] and paracardial adipose tissue are located. The thickness of this adipose tissue differed markedly between patients. The median cross sectional area of paracardial adipocytes was 12 (8.0–17) 102 μm². With IHC staining,
APN was found in parts of the adipose tissue, vascular endothelium (some patients only), and in collagen-rich regions. A-FABP was located in some of the adipocytes, nerves, arterioles and capillaries. Mesothelium and arterial smooth muscle cells did not stain for A-FABP or APN. Presence of detectable A-FABP and APN in adipocytes displayed marked regional heterogeneity (Fig 2). The percentage of paracardial adipocytes that was immunoreactive for A-FABP or APN varied considerably between patients (43 (0.0–94) and 63 (14–100) %, respectively).

Interrelationships and associations

In PF, there were no statistically significant relationships between the levels of the adipokines investigated while in P the levels of leptin and A-FABP were positively correlated (Table 2). As expected [1, 31], the circulating level of leptin increased with increasing BMI while the circulating concentration of APN was inversely correlated to BMI (Table 2). Also in PF, leptin levels were positively correlated to BMI but the concentrations of APN in PF displayed no significant relation to BMI.

Table 2 further summarizes associations between the concentrations of adipokines and patient characteristics listed in Table 1. The concentrations of leptin in both P and PF were each related to type 2 diabetes, BMI, circulating levels of glycated hemoglobin and to treatment with an inhibitor of the renin-angiotensin system. For A-FABP in P and PF there were fewer similarities. This discrepancy between the adipokine concentrations in the two compartments was even more marked for APN. APN in P, but not PF, was inversely related to CAD, BMI, and plasma triglycerides and positively correlated to the age of the patients (Table 2).
The size of the paracardial adipocytes was significantly larger in type 2 diabetic patients (13.7 (11.1–18.0) versus 10.2 (6.6–13.1) x 10^2 μm^2, p = 0.038) and in CAD patients (13.6 (10.7–18.0) versus 6.7 (5.9–9.9) x 10^2 μm^2, p = 0.0004) but was not correlated to BMI (p = 0.642, r = 0.0839), not related to the PF level of A-FABP (p = 0.735, r = 0.0611) and inversely related to the PF level of APN (p = 0.0364, r = -0.366). Paracardial adipocyte immunoreactivity for A-FABP or APN were significantly correlated (p = 0.0469, r = 0.3720) but not significantly related to adipocyte size (p = 0.352, r = -0.179 and p = 0.223, r = -0.218 respectively) or to the PF concentration of A-FABP or APN (p = 0.507, r = 0.124 and p = 0.460, r = 0.133, respectively).

**Discussion**

In pericardial fluid of cardiothoracic surgery patients, the concentration of leptin was comparable but the level of A-FABP markedly higher and that of APN considerably lower than in the circulating plasma. Leptin levels in pericardial fluid and plasma were correlated to most of the same patient characteristics while APN in pericardial fluid was unlike in the plasma not correlated to age, body mass index, type 2 diabetes, plasma triglycerides and CAD. The concentration of APN but not A-FABP in pericardial fluid was related to the size of paracardial adipocytes, whereas both adipokine concentrations in pericardial fluid were not related to the immunoreactivity of the adipocytes in the paracardial pericardium. These findings indicate that the pericardial cavity of cardiovascular disease patients is a pro-inflammatory atherogenic.
adipokine microenvironment determined by components of the heart rather than by the circulating hormones or paracardial adipose tissue.

Increased risk for metabolic and cardiovascular diseases associated with increased adiposity [1, 2] stimulated interests in signaling molecules secreted by adipose tissues [4–7]. These adipokines can reach the cardiovascular system as hormones via the circulation and as paracrine mediators produced by comparatively small adipose tissues that surround the heart and blood vessels. Hyperleptinemia and hypoadiponectinemia in obesity are strongly associated with type 2 diabetes but only moderately with CAD [32, 33]. Circulating levels of A-FABP increase with the number of stenotic coronary arteries [34]. On the other hand, the volume of EAT correlates positively with CAD in not only obese but also non-obese patients [8, 9, 15, 17]. Moreover, several classical vasoactive mediators and angiogenic growth factors are more abundant in the pericardial fluid than in the circulation of ischemic heart disease and heart failure patients [21, 23–25]. For these reasons we performed a small paired cross sectional comparison of concentrations of leptin, A-FABP and APN in pericardial fluid and venous plasma. Pericardial fluid was obtained at outset of coronary artery bypass or cardiac valve replacement surgery where the parietal pericardium must be opened to gain access to the heart. The characteristics of the patients that we investigated are comparable to those previously studied with respect to EAT volume and histology [10, 11, 15, 16, 18, 20] and coronary arteriolar endothelial dysfunction [35, 36]. Pericardial fluid was compared to a venous blood sample from the day before surgery. This is justified because earlier studies found no changes in the circulating levels of leptin and APN and an at most 50% increase of plasma A-FABP during the early steps of cardiothoracic surgery [37, 38].

Experimental animal evidence (reviewed by Beltowski [5]) links elevations in circulating levels of the 16 kDa protein leptin via loss of leptin function or leptin resistance to atherogenesis and CAD but findings in human patients are less convincing [32]. In line with earlier reports [5, 31, 39, 40] we observed that in human patients the circulating levels of leptin are positively correlated to BMI, type 2 diabetes and consequences thereof such as elevated HbA1c, but not CAD, age or plasma cholesterol and triglycerides. We found that leptin in pericardial fluid, which to the best of our knowledge was not reported before, is comparable to that in the venous plasma in terms of not only concentration but also relation to most of the same patient characteristics. In sharp contrast to leptin, marked quantitative and qualitative differences were observed for A-FABP and APN. Experimental animal evidence (reviewed by Xu and Vanhoutte [6]) links circulating levels of the 15 kDa protein A-FABP that can be secreted by adipocytes and macrophages, to cardiovascular diseases and findings in patients link it to the severity of CAD [34] and heart failure [27]. In our paired comparison, A-FABP was nine times more abundant in pericardial fluid than in circulating plasma and while plasma concentrations were significantly related to plasma HbA1c and leptin levels and to treatment with statins, pericardial fluid concentrations were not. Experimental evidence (reviewed by Hui et al. [4], Xu and Vanhoutte [6] and Mattu and Randeva [7]) links reductions of the circulating levels of the 90 (trimeric), 180 (hexameric) and >250 kDa protein APN to endothelial dysfunction and atherogenesis. Again the data available for patients are less convincing [33]. In our study, we confirmed the inverse relationships in CVD patients between circulating total APN on the one hand and CAD, BMI and plasma triglycerides on the other hand and the positive relation between circulating total APN with age and plasma HDL cholesterol described in earlier reports [4, 6, 31, 41]. Levels of APN in patient pericardial fluid, which were recently determined but not correlated to circulating plasma levels [10], were in our hands 4.5 times lower than in the circulation and not significantly related to any of the factors that seem to govern plasma APN levels with the exception of a weak association with plasma HDL cholesterol. Combined our findings indicate that the adipokine composition in pericardial fluid of cardiac and vascular
diseases patients differs quantitatively and qualitatively from that in the circulation. For instance, the leptin/APN and the A-FABP/APN ratio’s that are advanced as powerful diagnostic markers [41–43] are 5 and more than 30 times larger in the local pericardial fluid than in the circulation, respectively. Although adipokine levels differed markedly between both compartments, the circulating and pericardial concentrations of leptin, A-FABP and APN were strongly correlated. Thus plasma concentrations may be considered in future longitudinal studies estimating local pericardial changes of adipokines during progression and treatment of cardiac and coronary artery diseases. These will at best be qualitative in nature and underestimate imbalances between adipokine species.

The pericardial cavity is considered for local treatment of ischemic heart disease and myocardial infarcts by drugs, angiogenic growth factors and stem cells [44, 45]. Control of pericardial fluid composition is however poorly understood. Some authors consider it a protein poor ultrafiltrate of the plasma [46, 47] while others emphasize similarities to the interstitium of the heart [21, 22, 47]. Our observations of comparable contributions of low and high molecular weight APN isoforms in plasma and pericardial fluid and of different pericardial to plasma ratios for leptin and A-FABP along with earlier findings of elevated levels of lactate dehydrogenase (140 kDa) in pericardial fluid [46], are not compatible with the former view. We considered contributions of the paracardial adipose tissue lining the outer surface of the parietal pericardium. Paracardial adipocyte size was enlarged in diabetic and CAD patients as previously reported for epicardial adipocytes [48]. Mean paracardial adipocyte immunoreactivities for A-FABP and APN were interrelated but not related to adipocyte size in contrast to the negative associations between the size of subcutaneous and epicardial adipocytes and APN gene expression previously observed by Bambace et al [48]. We could not observe a significant relationship between mean paracardial adipocyte immunoreactivity and pericardial fluid levels of A-FABP and APN. This could indicate that there is no major contribution of paracardial adipose tissue to pericardial fluid levels of adipokines. For the two adipokines that we stained in parietal pericardium we observed marked regional heterogeneities. Thus in addition to differences between adipose tissues at different anatomical locations [1, 16–20, 49], adipokine biology seems to differ locally within a given adipose tissue. It will be of interest to verify in future investigations whether these regional heterogeneities are correlated to distances from blood vessels, capillaries or macrophages, in order to discriminate between differences from perivascular adipose tissue and influences of local oxygen tension and inflammation.

Study Limitations

In this cross sectional investigation of randomly selected cardiothoracic surgery patients a fair number of strong associations could be observed. The causal nature of these could not be addressed. The study was too small to appreciate influences of the more rare aspects in the study population such as female sex and specific medications, or to perform multivariate analysis. No pericardial fluid could be sampled from individuals without CVD or cardiovascular drug treatments. This may be partly remedied by studies in a sufficiently large relevant experimental animal model [50] and sampling of pericardial fluid from patients undergoing thoracic surgery for non-CVD [51]. Confounding influences of drugs such as statins and PPARγ agonists that have been observed to influence circulating levels and local expressions of adipokines [3, 4, 14] might be more difficult to deal with. At this stage we addressed only three proteins from a broad spectrum of candidate adipokines [1, 7, 17, 31] and future studies may want to address a broader panel of adipocyte derived signaling molecules. Our suggestions about the lack of relation between paracardial adipose tissue and pericardial fluid adipokine content are weakened by the absence of information on paracardial tissue volume which is not part of the
diagnostics of our elective cardiothoracic surgery patients. More importantly, we lack information on epicardial adipose tissue volume \[9, 11–13, 15, 16\], immunohistochemistry and adipokine secretion \[14, 16, 17, 19\] to propose this adipose tissue compartment as a determinant of pericardial fluid adipokine composition. Finally, whether the pericardial fluid adipokine profile i) represents spillover from the cardiac interstitium with potential for biomarker research of epicardial adipose tissue effects on CAD and ii) might in itself contribute to coronary atherogenesis, coronary microvascular dysfunction, arrhythmogenesis and heart failure, will require a broad variety of dedicated investigations.

**Supporting Information**

**S1 Fig.** Standard curve and specificity of adiponectin protein detection by Western blotting. (DOCX)

**Acknowledgments**

The authors thank Simone Rørdam Preil PhD from the Department of Clinical Biochemistry and Pharmacology (OUH) for assistance with the collection and handling of patient biopsies and characteristics and Inger Nissen from the Department of Cardiovascular and Renal Research (SDU) for assistance with immunohistochemistry.

**Author Contributions**

Conceived and designed the experiments: LMR YW JGRDM. Performed the experiments: AGIME IMEG KDN AX ES. Analyzed the data: AGIME PSJ KDN AX ES JGRDM. Contributed reagents/materials/analysis tools: AGIME PSJ KDN IMEG AX ES MLH AI LMR YW JGRDM. Wrote the paper: AGIME PSJ KDN IMEG AX ES MLH AI LMR YW JGRDM.

**References**

1. Hassan M, Latif N, Yacoub M. Adipose tissue: friend or foe? Nat Rev Cardiol. 2012; 9(12):689–702. doi: 10.1038/nrcardio.2012.148 PMID: 23149834.

2. Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5):968–77. PMID: 6219830.

3. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50(9):2094–9. PMID: 11522676.

4. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012; 165(3):574–90. doi: 10.1111/j.1476-5381.2011.01395.x PMID: 21457225; PubMed Central PMCID: PMCPMC3315032.

5. Beltowski J. Leptin and atherosclerosis. Atherosclerosis. 2006; 189(1):47–60. doi: 10.1016/j.atherosclerosis.2006.03.003 PMID: 16580676.

6. Xu A, Vanhoutte PM. Adiponectin and adipocyte fatty acid binding protein in the pathogenesis of cardiovascular disease. Am J Physiol Heart Circ Physiol. 2012; 302(6):H1231–40. doi: 10.1152/ajpheart.00765.2011 PMID: 22210749.

7. Mattu HS, Randeva HS. Role of adipokines in cardiovascular disease. J Endocrinol. 2013; 216(1):T17–36. doi: 10.1530/JOE-12-0232 PMID: 23166967.

8. Talman AH, Psaltis PJ, Cameron JD, Meredith IT, Seneviratne SK, Wong DT. Epicardial adipose tissue: far more than a fat depot. Cardiovasc Diagn Ther. 2014; 4(6):416–29. doi: 10.3978/j.issn.2223-3652.2014.11.05 PMID: 25610806; PubMed Central PMCID: PMC4278038.

9. Iacobellis G, Corradi D, Sharma AM. Epicardial adipose tissue: anatomic, biomolecular and clinical relationships with the heart. Nat Clin Pract Cardiovasc Med. 2005; 2(10):536–43. doi: 10.1038/ncpcardio0319 PMID: 16186852.
10. Iwayama T, Nitobe J, Watanabe T, Ishino M, Tamura H, Nishiyama S, et al. Role of epicardial adipose tissue in coronary artery disease in non-obese patients. J Cardiol. 2014; 63(5):344–9. doi: 10.1016/j.jcc.2013.10.002 PMID: 24230463.

11. Yerramasu A, Dey D, Venuraju S, Anand DV, Atwal S, Corder R, et al. Increased volume of epicardial fat is an independent risk factor for accelerated progression of sub-clinical coronary atherosclerosis. Atherosclerosis. 2012; 220(1):223–30. doi: 10.1016/j.atherosclerosis.2011.09.041 PMID: 22015177.

12. Mahabadi AA, Massaro JM, Rosito GA, Levy D, Murabito JM, Wolf PA, et al. Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J. 2009; 30(7):850–6. doi: 10.1093/eurheartj/ehn573 PMID: 19136488; PubMed Central PMCID: PMC3693564.

13. Iacobellis G, Ribaudo MC, Assael F, Vecchi E, Zappaterreno A, et al. Epicardial adipokines in obesity and metabolic syndrome: a new indicator of cardiovascular risk. J Clin Endocrinol Metab. 2003; 88(11):5163–8. doi: 10.1210/jc.2003-030698 PMID: 14602744.

14. Grosso AF, de Oliveira SF, Higuchi ME, Favarato D, Dallan LA, da Luz PL. Synergistic anti-inflammatory effect: simvastatin and pioglitazone reduce inflammatory markers of plasma and epicardial adipose tissue of coronary patients with metabolic syndrome. Diabetol Metab Syndr. 2014; 6(1):47. doi: 10.1186/1758-5996-6-47 PMID: 24684779; PubMed Central PMCID: PMC3987153.

15. Shimabukuro M, Hirata Y, Tabata M, Dagiwasumberel M, Sato H, Kurobe H, et al. Epicardial adipose tissue volume and adipocytokine imbalance are strongly linked to human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2013; 33(5):1077–84. doi: 10.1161/ATVBAHA.112.300829 PMID: 23471228.

16. Harada K, Amano T, Kataoka T, Takeshita M, Kunimura A, Takayama Y, et al. Impact of abdominal and epicardial fat on the association between plasma adipocytokines levels and coronary atherosclerosis in non-obese patients. Atherosclerosis. 2014; 237(2):671–6. doi: 10.1016/j.atherosclerosis.2014.10.014 PMID: 25463104.

17. Payne GA, Kohr MC, Tune JD. Epicardial perivascular adipose tissue as a therapeutic target in obesity-related coronary artery disease. Br J Pharmacol. 2012; 165(3):659–69. doi: 10.1111/j.1476-5381.2011.01370.x PMID: 21545577; PubMed Central PMCID: PMC3315038.

18. Pezeshkian M, Mahatabipour MR. Epicardial and subcutaneous adipose tissue Fatty acids profiles in diabetic and non-diabetic patients candidate for coronary artery bypass graft. Bioimpacts. 2013; 3 (2):83–9. doi: 10.5681/bi.2013.004 PMID: 23878791; PubMed Central PMCID: PMC3713874.

19. Mazurek T, Zhang L, Zalewski A, Mannion JD, Diehl JT, Arafat H, et al. Human epicardial adipose tissue is a source of inflammatory mediators. Circulation. 2003; 108(20):2460–6. doi: 10.1161/01.CIR.0000099542.57313.C5 PMID: 14581396.

20. Karastergiou K, Evans I, Ogston N, Miheisi N, Nair D, Kaski JC, et al. Epicardial adipokines in obesity and coronary artery disease induce atherogenic changes in monocytes and endothelial cells. Arterioscler Thromb Vasc Biol. 2010; 30(7):1340–6. doi: 10.1161/ATVBAHA.110.204719 PMID: 20395594.

21. Fujita M, Komeda M, Hasegawa K, Kihara Y, Nohara R, Sasayama S. Pericardial fluid as a new material for clinical heart research. Int J Cardiol. 2001; 77(2–3):113–8. PMID: 11182172.

22. Selme C, Antal M, Horkay F, Merkely B, Bíró L, et al. Enhanced accumulation of pericardial fluid ferritin in patients with coronary artery disease. Jpn Heart J. 2003; 44(5):633–44. PMID: 14587645.

23. Watanabe M, Kawaguchi S, Nakahara H, Hachimaru T. The roles of natriuretic peptides in pericardial fluid of patients with heart failure. Circ J. 2009; 73(3):159–63. doi: 10.1210/cj.2009-0018 PMID: 19301292.

24. Iwayama T, Nitobe J, Watanabe T, Ishino M, Tamura H, Nishiyama S, et al. Role of epicardial adipose tissue in coronary artery disease in non-obese patients. J Cardiol. 2014; 63(5):344–9. doi: 10.1016/j.jcc.2013.10.002 PMID: 24230463.

25. Nair D, Kaski JC, Evans I, Ogston N, Miheisi N, Nair D, Kaski JC, et al. Circulating adipocyte fatty acid-binding protein levels independently predict incident cardiovascular events in men in a population-based cohort. Arterioscler Thromb Vasc Biol. 2014; 34(11):2457–64. doi: 10.1161/ATVBAHA.114.303718 PMID: 25189569.

26. Liu M, Zhou M, Bao Y, Xu Z, Li H, Zhang H, et al. Circulating adipocyte fatty acid-binding protein levels independently associated with heart failure. Clin Sci (Lond). 2013; 124(2):115–22. doi: 10.1042/CS20120004 PMID: 23013043.
formation of its high molecular weight oligomeric complex. J Biol Chem. 2006; 281(24):16391–400. doi: 10.1074/jbc.M513907200 PMID: 16621799.

29. Chen HC, Farese RV. Determination of adipocyte size by computer image analysis. J Lipid Res. 2002; 43(6):986–9. PMID: 12032175.

30. Bloksgaard M, Leurgans TM, Nissen I, Jensen PS, Hansen ML, Brewer JR, et al. Elastic organization of pig and cardiovascular disease patients' pericardial resistance arteries. J Vasc Res. 2015; 52(1):1–11. doi: 10.1159/000367548 PMID: 25833410.

31. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: facts and expectations at the beginning of the 21st century. Metabolism. 2015; 64(1):131–45. doi: 10.1016/j.metabol.2014.10.016 PMID: 25497344.

32. Sattar N, Wannamethee G, Sarwar N, Chernova J, Lawlor DA, Kelly A, et al. Leptin and coronary heart disease: prospective study and systematic review. J Am Coll Cardiol. 2009; 53(2):167–75. doi: 10.1016/j.jacc.2008.09.035 PMID: 19130985.

33. Sattar N, Wannamethee G, Sarwar N, Tchernova J, Cherry L, Wallace AM, et al. Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. 2006; 114(7):623–9. doi: 10.1161/CIRCULATIONAHA.106.1618918 PMID: 16894037.

34. Rhee EJ, Lee WK, Park CY, Oh KW, Kim BJ, Sung KC, et al. The association of serum adipocyte fatty acid-binding protein with coronary artery disease in Korean adults. Eur J Endocrinol. 2009; 160(2):165–72. doi: 10.1530/EJE-08-0665 PMID: 19001529.

35. Beleznai T, Feher A, Spielvogel D, Lansman SL, Bagi Z. Arginase 1 contributes to diminished coronary arteriolar dilation in patients with diabetes. Am J Physiol Heart Circ Physiol. 2011; 300(3):H777–83. doi: 10.1152/ajpheart.00831.2010 PMID: 21217072; PubMed Central PMCID: PMCPMC3064303.

36. Larsen BT, Bubolz AH, Mendoza SA, Pritchard KA, Gutterman DD. Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species. Arterioscler Thromb Vasc Biol. 2009; 29(5):739–45. doi: 10.1161/ATVBAHA.108.169367 PMID: 19213944; PubMed Central PMCID: PMCPMC2727937.

37. Kotulak T, Drapalova J, Lips M, Lacinova Z, Kramar P, Riha H, et al. Cardiac surgery increases serum concentrations of adipocyte fatty acid-binding protein and its mRNA expression in circulating monocytes but not in adipose tissue. Physiol Res. 2014; 63(1):83–94. PMID: 24182337.

38. Kremen J, Dolinkova M, Krajickova J, Blaha J, Anderlova K, Lacinova Z, et al. Increased subcutaneous and epicardial adipose tissue production of proinflammatory cytokines in cardiac surgery patients: possible role in postoperative insulin resistance. J Clin Endocrinol Metab. 2006; 91(11):4620–7. doi: 10.1210/jc.2006-1044 PMID: 16894037.

39. Fischer S, Hanefeld M, Haffner SM, Fuchs C, Schwanebeck U, Köhler C, et al. Insulin-resistant patients with type 2 diabetes mellitus have higher serum leptin levels independently of body fat mass. Acta Diabetol. 2002; 39(3):105–10. doi: 10.1007/s005920200027 PMID: 12357293.

40. Correia ML, Haynes WG. Leptin, obesity and cardiovascular disease. Curr Opin Nephrol Hypertens. 2004; 13(2):215–23. PMID: 15202616.

41. Jin J, Peng DQ, Yuan SG, Zhao SP, Ning XH, Wang SH, et al. Serum adipocyte fatty acid binding proteins and adiponectin in patients with coronary artery disease: the significance of A-FABP/adiponectin ratio. Clin Chim Acta. 2010; 411(21–22):1761–5. doi: 10.1016/j.cca.2010.07.031 PMID: 20688054.

42. Zaletel J, Barlovic DP, Prezelj J. Adiponectin-leptin ratio: a useful estimate of insulin resistance in patients with Type 2 diabetes. J Endocrinol Invest. 2010; 33(8):514–8.

43. Mostowik M, Gajos G, Zalewski J, Nesserer J, Undas A. Omega-3 polyunsaturated fatty acids increase plasma adiponectin to leptin ratio in stable coronary artery disease. Cardiovasc Drugs Ther. 2013; 27(4):289–95. doi: 10.1007/s10557-013-6457-x PMID: 23584593; PubMed Central PMCID: PMCPMC3709088.

44. Rubanyi GM. Mechanistic, technical, and clinical perspectives in therapeutic stimulation of coronary collateral development by angiogenic growth factors. Mol Ther. 2013; 21(4):725–38. doi: 10.1038/mt.2013.13 PMID: 23403495; PubMed Central PMCID: PMCPMC3615642.

45. Núñez García A, Sanz-Ruiz R, Fernández Santos ME, Fernández-Avilés F. "Second-generation" stem cells for cardiac repair. World J Stem Cells. 2015; 7(2):352–67. doi: 10.4252/wjsc.v7.i2.352 PMID: 25815120; PubMed Central PMCID: PMCPMC4369492.

46. Ben-Horin S, Shinfeld A, Kachel E, Chetrit A, Livneh A. The composition of normal pericardial fluid and its implications for diagnosing pericardial effusions. Am J Med. 2005; 118(6):636–40. doi: 10.1016/j.amjmed.2005.01.066 PMID: 1592695.

47. Vogiatzidis K, Zarogiannis SG, Aidonidis I, Solenov EI, Molyvdas PA, Gourgoulianis KI, et al. Physiology of pericardial fluid production and drainage. Front Physiol. 2015; 6:62. doi: 10.3389/fphys.2015.00062 PMID: 2585256; PubMed Central PMCID: PMCPMC4364155.
48. Bambace C, Telesca M, Zoico E, Sepe A, Olioso D, Rossi A, et al. Adiponectin gene expression and adipocyte diameter: a comparison between epicardial and subcutaneous adipose tissue in men. Cardiovasc Pathol. 2011; 20(5):e153–6. doi:10.1016/j.carpath.2010.07.005 PMID: 20829073.

49. Fitzgibbons TP, Czech MP. Epicardial and perivascular adipose tissues and their influence on cardiovascular disease: basic mechanisms and clinical associations. J Am Heart Assoc. 2014; 3(2):e000582. doi:10.1161/JAHA.113.000582 PMID: 24595191; PubMed Central PMCID: PMCPMC4187500.

50. Al-Mashhadi RH, Sørensen CB, Kragh PM, Christoffersen C, Mortensen MB, Tolbod LP, et al. Familial hypercholesterolemia and atherosclerosis in cloned minipigs created by DNA transposition of a human PCSK9 gain-of-function mutant. Sci Transl Med. 2013; 5(166):166ra1. doi:10.1126/scitranslmed.3004853 PMID: 23283366.

51. Xiang F, Guo X, Chen W, Wang J, Zhou T, Huang F, et al. Proteomics analysis of human pericardial fluid. Proteomics. 2013; 13(17):2692–5. doi:10.1002/pmic.201200317 PMID: 23797974.